SI-BONE, Inc. Common Stock
SIBNSI-BONE, Inc. is a medical device company specializing in minimally invasive solutions for the treatment of musculoskeletal disorders of the sinonasal and sacroiliac joint regions. The company develops and commercializes products designed to improve patient outcomes by addressing conditions related to the pelvis and sacroiliac joint, with a focus on innovative, image-guided procedures.
Company News
Si-Bone (SIBN) stock surged nearly 20% on Tuesday following strong first-quarter 2026 results. The medical device company reported $52.6 million in revenue (up 11% YoY) and significantly narrowed its net loss to $4.3 million. The company also received FDA clearance for its iFuse INTRA Ti implant system and raised full-year guidance to $230-233 mi...
Smith+Nephew announced it will showcase advanced orthopaedic technologies at AAOS 2026, including its CORI handheld robotic surgical system for hip, knee and shoulder arthroplasty, new trauma solutions like the EVOS plating system, and an expanded ASC portfolio. The company also announced distribution agreements with SI-BONE for pelvic fracture s...
Smith+Nephew will showcase its rotator cuff repair portfolio at AAOS 2026, featuring the newly acquired Tendon Seam Repair System and REGENETEN Bioinductive Implant. The company also announced exclusive US distribution agreements with RMR Ortho for A'TOMIC nitinol fixation technology and SI-BONE for their iFuse TORQ portfolio, expanding its ortho...
SI-BONE announced preliminary Q4 2025 revenue of $56.2-$56.3 million (~15% growth) and full year 2025 revenue of $200.8-$200.9 million (~20% growth). The company reported ~1,640 active U.S. physicians (18% increase) and cash equivalents of ~$147.7 million with net cash generation of ~$2.0 million in Q4. Final audited results will be provided in l...
SI-Bone reported strong Q3 results with 21% revenue growth, narrowed net losses, and increased physician adoption, leading to a significant stock price surge.
